Return to homepagePandemic Pact

Nucleoside analogues as anti-CoV-2 drugs]

  • Funded by ANR, Other Funders (France)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $143,718.44

  • Funder

    ANR, Other Funders (France)

  • Principal Investigator

    Christophe MATHE

  • Research Location

    France

  • Lead Research Institution

    Université Montpellier

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The NucleoCoV2 project coordinated by Christophe Mathé (Institut des Biomolécules Max Mousseron - Faculty of Pharmacy - University of Montpellier) concerns the discovery of new anti-Covid-19 agents. It aims to identify nucleoside analogs, compounds that belong to a well-known class of antivirals with proven efficacy (HIV, HSV, HCV), and to develop in vitro models for the evaluation of drug candidates.